drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (adoptive cell transfer)
drug_description
Autologous, ex vivo–expanded tumor-reactive T cells used for adoptive cell therapy to recognize patient-specific tumor antigens and kill cancer cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lymphocytes, Tumor-Infiltrating
drug_category
TUMOR INFILTRATING LYMPHOCYTES
drug_class
Unedited cells
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous tumor-infiltrating T cells expanded ex vivo are reinfused to target cancer via their native TCRs, recognizing patient-specific peptide–MHC tumor antigens and killing tumor cells through cytotoxic granule release and cytokine-mediated immune activation; lymphodepletion and IL-2 support engraftment and persistence.
drug_name
Tumor Infiltrating Lymphocytes (TIL)
nct_id_drug_ref
NCT06530303